Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 82009-021

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 82009-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container (Container)

Label for Clopidogrel bisulfate 75 mg film-coated tablets by Quallent Pharmaceuticals Health LLC. The label indicates 90 tablets per container with the NDC 82009-021-90. It includes dosage details, storage instructions, a barcode, and advising pharmacists to dispense the Medication Guide to each patient.*

FDA Label Image

Figure1 (Figure1)

A horizontal bar chart illustrating the effect of co-administered PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the active metabolite AUC mean and 90% confidence interval. The x-axis ranges from 0.4 to 1.4, showing relative effect values with confidence bars for each PPI.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting cumulative event rates over 12 months of follow-up, comparing Clopidogrel (+ aspirin) versus placebo (+ aspirin). The vertical axis shows cumulative event rate percentage, while the horizontal axis represents months of follow-up. Clopidogrel shows a lower cumulative event rate than placebo throughout the period.*

FDA Label Image

Figure3 (Figure3)

Forest plots showing hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel bisulfate versus placebo. The subgroups include age, gender, race, elevated cardiac enzyme status, diabetes, previous myocardial infarction, previous stroke, heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use, with the overall effect shown at the bottom of each plot.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing the percentage of deaths before first discharge over 28 days between placebo and Clopidogrel treatments. The vertical axis shows % dead before first discharge, and the horizontal axis shows days since randomization. The graph indicates 8.1% deaths for placebo and 7.5% for Clopidogrel, with a noted 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure5 (Figure5)

A line graph depicting the percentage of patients experiencing death, reinfarction, or stroke before first discharge over 28 days since randomization. Two lines represent data for placebo and clopidogrel groups, showing a lower event percentage with clopidogrel. The graph includes a statistical note indicating a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Figure6 (Figure6)

A forest plot chart showing odds ratios with 99% confidence intervals for Clopidogrel bisulfate versus placebo in various subgroups. The subgroups include gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use, with numerical data of events and percentage for Clopidogrel and placebo groups shown on the left side.*

FDA Label Image

Figure7 (Figure7)

A cumulative event rate line graph comparing fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel and Aspirin. The y-axis shows the cumulative event rate percentage, and the x-axis represents months of follow-up, indicating event rates increase over time with a statistical value of P=0.045.*

FDA Label Image

Figure8 (Figure8)

A forest plot comparing the hazard ratio (with 95% confidence intervals) of Clopidogrel versus Aspirin across different qualifying conditions: Stroke, Myocardial Infarction (MI), Peripheral Artery Disease (PAD), and Overall. The plot visually indicates which treatment is favored in each condition based on hazard ratios and sample sizes.*

FDA Label Image

Structure (Structure)

Chemical structure of clopidogrel bisulfate, showing its molecular arrangement including a bicyclic ring system, chlorine-substituted aromatic ring, and sulfuric acid hydrate component (H2SO4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.